louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03121859: Analgesic Current Therapies for Chronic Neck Pain
Official title: Does The Use Of Analgesic Current Therapies Increase The Effectiveness Of Neck Stabilization Exercises For Improving Pain, Disability, Mood, And Quality Of Life In Chronic Neck Pain? A Randomized, Controlled, Single-Blind Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Neck Pain
Keywords: TENS
interferential current therapy
Chronic neck pain
Lead sponsor: Ege University
Sponsor class: OTHER
First posted: 2017-04-20
Enrollment: 81
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Does the use of analgesic current therapies increase the effectiveness of neck stabilization exercises for improving pain, disability, mood, and quality of life in chronic neck pain? a randomized, controlled, single-blind study

Detailed description: Analgesic therapies; such as interferential current (IFC) and transcutaneous electrical nerve stimulation (TENS) have been applied solo or combined with exercise for management of neck pain (NP), however, the efficacy of these combinations are unclear. In this study, our objective were to determine if TENS or IFC increase the effectiveness of neck stabilization exercises on pain, disability, mood, and quality of life for chronic NP. 81 patients with chronic NP were included in the study. Patients were randomly assigned into 3 groups; Group I: neck stabilization exercise, Group II: TENS+ neck stabilization exercise and Group III: IFC+ neck stabilization exercise. Patients' pain levels (visual analogue scale (VAS)), quality of life (short form- 36), mood (Beck depression inventory (BDI)), levels of disability (Neck Pain and Disability Index) and the need for analgesics were evaluated prior to treatment, at 6th and 12th week follow-up. All participants had group exercise accompanied by a physiotherapist for 3 weeks and an additional 3 weeks of home exercise program.

Eligibility criteria: Inclusion Criteria:

* Both genders between 20-50 years, had chronic neck pain

Exclusion Criteria: Having disc hernia that causes neurological deficit

* Having malignity,
* Having neck pain secondary neurological or vascular disease.
* Pregnancy
* Having psychiatric disease
* Having arthritic disease
* Having any contraindication for electrotherapy

Primary outcomes:
measure: Change from baseline VAS (Visual analog scale) at 6th and 12th weeks
timeFrame: Up to12 weeks
Secondary outcomes:
measure: Change from baseline quality of life (short form- 36) at 6th and 12th weeks
timeFrame: Up to 12 weeks
measure: Change from baseline Beck depression inventory (BDI) at 6th and 12th weeks
timeFrame: Up to 12 weeks
measure: Change from baseline Neck Pain and Disability Index at 6th and 12th weeks
timeFrame: Up to 12 weeks
Other outcomes:
Locations:
city: Afyon
country: Turkey
facility: Hilal Yesil
state: Eyalet/Yerleşke
Study officials:
References:
Clinical trial NCT02365259: Phototherapy in Persons With Multiple Sclerosis
Official title: Effect of UVB Phototherapy on Serum Vitamin D in Persons With Multiple Sclerosis; a Placebo Controlled Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Multiple Sclerosis
Lead sponsor: University of Illinois at Urbana-Champaign
Sponsor class: OTHER
First posted: 2015-02-18
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The current study examines the effect of phototherapy equipped with Narrow Band UVB lamps on vitamin D production in persons with MS.

Detailed description: Participants will be exposed to phototherapy according to the 2014 Guidelines issued by the American Academy of Dermatology 3 days per week over an 8-week period.

Eligibility criteria: Inclusion Criteria:

* Female with multiple sclerosis

Exclusion Criteria:

* Inability to stand still in a stabilized fashion without risk of falling for up to 6 minutes
* Known medical history of calcium disorder or knowledge of high calcium levels
* Known medical history of hyper-parathyroidism
* Current supplementation with oral vitamin D
* Known allergy to vitamin D
* History of cancer of any type including but not limited to skin cancer
* Obesity defined as BMI \> 30
* Known history of fat malabsorption conditions (i.e., steatorrhea)
* Current use of anti-epileptic medication
* Current use of glucocorticoids
* Fitzpatrick skin types I and VI using the Fitzpatrick skin type analysis
* Recent use of tanning facilities

Primary outcomes:
measure: Change from Baseline in Serum Vitamin D at 4 and 8 weeks
timeFrame: 0, 4, and 8 weeks
Secondary outcomes:
measure: Change from Baseline in Walking Speed at 4 and 8 weeks
timeFrame: 0, 4, and 8 weeks
measure: Change from Baseline in Cognitive Function at 4 and 8 weeks
timeFrame: 0, 4, and 8 weeks
measure: Change from Baseline in Mood State at 4 and 8 weeks
timeFrame: 0, 4, and 8 weeks
Other outcomes:
Locations:
city: Urbana
country: United States
facility: Exercise Neuroscience Research Laboratory
state: Illinois
Study officials:
affiliation: University of Illinois at Urbana-Champaign
name: Robert W Motl, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00378859: The Effect of Milk and Meat on IGFs in Prepubertal Boys
Official title: The Effect of Milk and Meat on IGFs in Prepubertal Boys
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Growth Disorders
Metabolic Syndrome
Keywords: Children
Milk
Meat
Animal Protein
Growth Factors
IGF-I
IGFBP-3
Insulin
Lead sponsor: University of Copenhagen
Sponsor class: OTHER
First posted: 2006-09-21
Enrollment: 24
Sex: MALE
Minimum age (years): 8
Maximum age (years): 8
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The objective of the study is to examine whether a 7-day high protein intake from either milk or meat in healthy, prepubertal children can increase fasting levels of serum IGF-I, IGFBP-3 and IGF-I/IGFBP-3 as well as insulin, glucose and HOMA insulin reststance, HOMA beta cell function and amino acids.

Detailed description: The objective of the study is to examine whether a high protein intake (PI) from either milk or meat, at a level often seen in late infancy, in healthy, prepubertal children can increase fasting levels of serum IGF-I, IGFBP-3 and IGF-I/IGFBP-3 as well as insulin, glucose and HOMA insulin reststance, HOMA beta cell function and amino acids.

IGF-I levels are positively associated with growth velocity in children and some studies suggest that a high animal PI can stimulate growth. During protein deprivation IGF-I decrease, but it is unknown whether a high PI can increase s-IGF-I in well-nourished children.

Insulin is also a growth factor, and studies have found that postprandially, milk possess some insulinotrophic effect not related to its carbohydrate content. However, the effect on fasting insulin in children is unknown.

Design: Twenty-four 8-y-old boys are asked to take either 1.5 l of skimmed milk (n=12) or the same amount of protein as 250 g low fat meat (n=12) daily for seven days. The remaining diet they can choose freely. At baseline and after seven days, anthropometrical variables are measured, diet is registered (3-d weighed records), and the blood analytes are determined after fast.

Eligibility criteria: Inclusion Criteria:

* habital milk intake more than 500 mL/d
* willing to increase intake of milk or meat considerably for one week

Exclusion Criteria:

* chronic illnesses
* children who suffer from any condition likely to affect their protein metabolism or growth

Primary outcomes:
measure: IGF-I
measure: IGFBP-3
measure: Insulin
measure: Glucose
measure: Aminogram
Secondary outcomes:
measure: Blood Pressure
measure: Kidney Size
measure: Urea Nitrogen
measure: Adiponectin
measure: Leptin
measure: Ghrelin
measure: Osteocalcin
measure: BAP
measure: CTX
Other outcomes:
Locations:
city: Frederiksberg C
country: Denmark
facility: Institute of Human Nutrition, Rolighedsvej 30
Study officials:
affiliation: Institute of Human Nutrition, Rolighedsvej 30, DK-1958 Frederiksberg C, Denmark
name: Kim F Michaelsen, Dr Med Sci
role: STUDY_CHAIR
References:
Clinical trial NCT01056575: Study to Evaluate the Potential for Interaction Between OC000459 and CYP 450 3A4
Official title: An Open Label Balanced Study in Healthy Subjects to Evaluate the Potential for Cytochrome P 450 3A4 Induction by Oral OC000459 Using Oral Midazolam as a Probe
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Lead sponsor: Oxagen Ltd
Sponsor class: INDUSTRY
First posted: 2010-01-26
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This will be an open label, sequential study of midazolam (dose 5 mg orally) followed by midazolam (5 mg orally) given after dosing with OC000459 100 mg twice daily for 6.5 days. Twenty subjects will be included to ensure at least 16 subjects with analysable PK data. PK sampling for midazolam and 4-hydroxymidazolam plasma concentrations will continue for up to and including 24 hours after dosing with midazolam on both occasions.


Eligibility criteria: Inclusion Criteria:

* Judged to be in good health at screening (blood tests, physical examination, medical history)

Exclusion Criteria:

* Evidence of a clinically significant underlying medical condition that in the opinion of the Investigator would represent a risk to study participation.

Primary outcomes:
measure: Ratio of exposure of midazolam and 4-hydroxymidazolam (without/with exposure to OC000459) as measured by plasma AUC0-t and Cmax for midazolam and its active metabolite 4-hydroxymidazolam.
timeFrame: 6.5 days
Secondary outcomes:
measure: Additional PK parameters of midazolam and its active metabolite 4-hydroxymidazolam
timeFrame: 6.5 days
measure: Safety and tolerability of OC000459
timeFrame: 6.5 days
Other outcomes:
Locations:
city: Merthyr Tydfil
country: United Kingdom
facility: Simbec Research Ltd
Study officials:
affiliation: Simbec Research
name: Salvatore Febbraro, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02222675: Conserving Breast Surgery - Comparison of Conventional With Sonography
Official title: Comparison of Sonographically Assisted With Conventionally Breast Surgery - Prospective, Randomised, Multicenter, Parallel Group Study With Two Study Arms
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Surgery
Lead sponsor: University Hospital Tuebingen
Sponsor class: OTHER
Collaborators: name: University Women's Hospital Tübingen
First posted: 2014-08-21
Enrollment: 46
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Aim of the study is to test whether surgical removal of a tumor under sonographic control as compared to conventional method reduces the rate of resections and local relapse


Eligibility criteria: Inclusion Criteria:

* 18 to 70 years
* Female
* Presurgical validated breast cancer

Exclusion Criteria:

* Sonographically not defined report
* Lobular breast cancer
* Extensive ductal carcinoma in situ

Primary outcomes:
measure: Rate of second tumor resections
timeFrame: Five years
Secondary outcomes:
Other outcomes:
Locations:
city: Tübingen
country: Germany
facility: University Women's Hospital
Study officials:
References:
citation: Hoffmann J, Marx M, Hengstmann A, Seeger H, Oberlechner E, Helms G, Rohm C, Ott C, Wallwiener D, Stabler A, Wiesinger B, Hartkopf AD, Brucker SY, Hahn M. Ultrasound-Assisted Tumor Surgery in Breast Cancer - A Prospective, Randomized, Single-Center Study (MAC 001). Ultraschall Med. 2019 Jun;40(3):326-332. doi: 10.1055/a-0637-1725. Epub 2018 Jul 5.
Clinical trial NCT00493675: Biodegradable Biliary Stent for Post Operative Cystic Duct Leakage
Official title: Biodegradable Biliary Stent for Post Operative Cystic Duct Leakage. Pilot Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Cyst
Keywords: Cystic duct leakage
Lead sponsor: Tampere University
Sponsor class: OTHER
First posted: 2007-06-28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Endoscopic sphincterotomy and temporary stenting is a routine treatment for post cholecystectomy cystic duct leakage. The draw back is that the plastic stent need to be removed later in a second intervention. Our studies with animal models have demonstrated that biodegradable biliary stent is at least as good as conventional plastic stent to heal that kind of leakage. In this pilot study the biodegradable biliary stent is inserted endoscopically to patients with confirmed cystic duct leakage to demonstrate the efficacy in human setting.


Eligibility criteria: Inclusion Criteria:

* Patients with confirmed post cholecystectomy cystic duct leakage requiring endoscopic treatment

Primary outcomes:
measure: Clinical healing of bile leakage
timeFrame: 1 month
Secondary outcomes:
measure: Laboratory tests for liver function, ultra sound for bile collections and bile duct diameter and abdominal plain X-ray for stent degradation
timeFrame: 6 months
Other outcomes:
Locations:
city: Tampere
country: Finland
facility: Tampere University Hospital
Study officials:
affiliation: Tampere University Hospital
name: Juhani A Sand, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06523075: Host Dysregulation-Driven Sepsis Prediction Model
Official title: Construction and Validation of a Sepsis Prediction Model Based on Dysregulation of Host Response
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sepsis
Lead sponsor: Second Affiliated Hospital of Wenzhou Medical University
Sponsor class: OTHER
First posted: 2024-07-26
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with Infection or Suspected Infection

Brief summary: The aim of this study is to identify risk factors associated with sepsis and to construct a predictive model for sepsis. This will provide an objective theoretical and empirical foundation for the diagnosis, assessment, and management of sepsis in our country.The primary questions addressed are:

What are the risk factors for the development of sepsis? How do we improve the prognosis of sepsis?


Eligibility criteria: Inclusion Criteria:

* Patients with Infection or Suspected Infection

Exclusion Criteria:

* Patients with Autoimmune Diseases
* Pregnant Women
* Patients with Advanced-Stage Cancer and Systemic Metastasis

Primary outcomes:
measure: Sepsis
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Wenzhou
country: China
facility: Xiue Ye
state: Zhejiang
city: Wenzhou
country: China
facility: The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University,
state: Zhejiang
Study officials:
References:
Clinical trial NCT00319059: The Influence of the 34C>T Variant in the AMPD1 Gene Ischemic Tolerance
Official title: The Influence of the 34C>T Variant in the AMPD1 Gene on Individual Susceptibility for Ischemia-reperfusion.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: AMPD
Ischemic Tolerance
Lead sponsor: Radboud University Medical Center
Sponsor class: OTHER
Collaborators: name: ZonMw: The Netherlands Organisation for Health Research and Development
First posted: 2006-04-27
Enrollment: 14
Sex: MALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Previous epidemiological studies have shown that in cardiovascular patients, the 34C\>T variant in the gene encoding for the enzyme Adenosine Mono Phosphate Deaminase (AMPD1) is associated with prolonged survival.

The 34 C\>T variant encodes a severely truncated, metabolically inactive protein. We hypothesize that during ischemia, in these patients AMP in preferentially converted into adenosine instead of IMP. Adenosine receptor stimulation, in turn, will increase resistance to ischemia-reperfusion in the myocardial tissue.

To test this hypothesis, 7 male healthy volunteers heterozygous for the 34C\>T variant will be selected from 100 healthy volunteers, which we have previously genotyped. These subjects will be compared with 7 matched control subjects. Individual ischemic tolerance will be assessed in the thenar muscle using 99mTc-Annexin A5 scintigraphy.

Briefly, the circulation of the nondominant forearm will be interrupted for 10 minutes by inflation of an upperarm cuff to 200mmHg en concomitantly, the subjects will perform isometric rhythmic handgripping until exhaustion. Immediately upon reperfusion, 400 MBq of 99mTc-Annexin A5 will be administered intravenously. Finally, 1 and 4 hours post-injection, scintigrapghi imaging of both hand will be performed. Targeting of annexin A5 will be expressed as percentage difference between the experimental and control hand.


Eligibility criteria: Inclusion Criteria:

* male
* 18-40 years
* healthy
* AMPD1 34C\>T variant (heterozygous) or matched control

Exclusion Criteria:

* cardiovascular / pulmonary disease
* diabetes / hypertension

Primary outcomes:
measure: 99mTc-Annexin A5 targeting
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Radboud University Medical Center
name: Gerard Rongen, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01608659: An Observational Retrospective Study to Evaluate Treatment Patterns of Botulinum Toxin Type A
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Facial Rhytides
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2012-05-31
Enrollment: 110
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects treated for glabellar lines (hyperfunctional facial lines) with botulinum toxin Type A

Brief summary: This is a retrospective chart review to evaluate treatment patterns of botulinum toxin Type A for the treatment of facial lines.


Eligibility criteria: Inclusion Criteria:

* Previously treated for glabellar lines (hyperfunctional facial lines) with botulinum toxin Type A preparation
* Received 2 treatment cycles wtih botulinum toxin Type A (BOTOX®) prior to at least 1 treatment with botulinum toxin Type A (Xeomin®)

Exclusion Criteria:

* None

Primary outcomes:
measure: Average Total Dose Per Treatment Period
timeFrame: 24 Months
Secondary outcomes:
measure: Inter-Injection Interval Duration of Each Treatment Period
timeFrame: 24 Months
measure: Percent of Subjects Reporting Satisfaction With Treatment Effects
timeFrame: 24 Months
Other outcomes:
Locations:
city: Buenos Aires
country: Argentina
Study officials:
affiliation: Allergan
name: Medical Director
role: STUDY_DIRECTOR
References:
citation: Banegas RA, Farache F, Rancati A, Chain M, Gallagher CJ, Chapman MA, Caulkins CA. The South American Glabellar Experience Study (SAGE): a multicenter retrospective analysis of real-world treatment patterns following the introduction of incobotulinumtoxinA in Argentina. Aesthet Surg J. 2013 Sep 1;33(7):1039-45. doi: 10.1177/1090820X13503475. Epub 2013 Aug 29.
Clinical trial NCT01308359: Use of Glucose and Saline for Fetal Movement Perception
Official title: Impact of Glucose Administration on Perception of Fetal Movements
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Fetal Movement Perception
Keywords: fetal movement
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
First posted: 2011-03-04
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the hypothesis that glucose administration increases fetal movement perception by the pregnant woman.


Eligibility criteria: Inclusion Criteria:

* Healthy parturients with singleton pregnancy during 3rd trimester

Exclusion Criteria:

* Any maternal medical condition (Diabetes, hypertension), multiple pregnancy, fetal anomaly, polyhydramnios

Primary outcomes:
measure: fetal movements as perceived by the mother
timeFrame: one hour
Secondary outcomes:
Other outcomes:
Locations:
city: Tel Aviv
country: Israel
facility: Lis Maternity Hospital, Tel Aviv Sourasky Medical Center
Study officials:
affiliation: Lis Maternity Hospital
name: Ariel Many, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03353259: Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery
Official title: Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
PHASE3
Conditions: Chronic Subdural Hematoma
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
First posted: 2017-11-27
Enrollment: 382
Sex: ALL
Minimum age (years): 55
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Primary objectives of the study are to investigate whether adjuvant treatment in the form of Tranexamic acid (Cyklokapron) and Tocilizumab (RoAcmera) to surgery in patients with chronic subdural hematomaina can:

1. effectively decrease the rate of lesion recurrence requiring re-operation,
2. effectively shorten the time of lesion resolution.

Secondary objectives of the study are:1) assess the postoperative functional outcome and quality of life of participants, 2) assess the postoperative mortality of participants, 3) assess the treatment safety data, 4) assess the cure rate of participants.

Detailed description: Primary endpoints in the study are: 1) determine postoperative recurrence requiring reoperation using clinical examination and CT imaging, 2) determine the time period necessary to complete healing using clinical examination and CT imaging.

Secondary endpoints in the study are: 1) to determine the functional outcome and quality of life of the participants using questionnaires, 2) to determine the mortality of the participants related to chronic subdural hematoma, 3) to determine the treatments complications and adverse events of the participants, 4) to determine the curation using clinical examination and CT imaging.

Eligibility criteria: Inclusion Criteria:

* patients with informed consent, without presenting of any known contraindication for the use of Tranexamic acid and Tocilizumab.

Exclusion Criteria:

* patients or relatives who refused to consent, presenting of any known contraindication for the use of Tranexamic acid and Tocilizumab.

Primary outcomes:
measure: Efficacy of Tocilizumab (RoActemra) and Tranexamic acid (Cyklokapron) used as Adjuncts to Chronic Subdural Hematoma Surgery Regarding Postoperative Recurrence
timeFrame: 6 months period after the initial surgery.
Secondary outcomes:
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Milo Stanisic
Study officials:
affiliation: Oslo University Hospital
name: Milo Stanisic
role: PRINCIPAL_INVESTIGATOR
References: